Author

S. Naik

h-index 40 View on Semantic Scholar

We have 3 of 129 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Upregulation of CD90 correlates with T lineage commitment at the DN2a stage of T cell development

Early thymic progenitors (ETPs) retain the potential for alternative fates but commit to the T-cell lineage as they progress through the CD4−CD8− double-negative (DN) thymocyte stages early in T-cell development. Current evidence suggests that T-lineage commitment occurs during the transition from the DN2a to DN2b stag...

Dhruti Parikh, Karen Gu, Sara Tomei et al. · Frontiers in Immunology · 0 citations

Open access Sep 2026

γδ T cells modulate anti-tumor immunity in small cell lung cancer.

Small cell lung cancer (SCLC) is a highly aggressive neoplasm with limited sensitivity to anti-PD-(L)1 blockade, which is likely caused by the epigenetic silencing of MHC-I. Elucidating MHC-I-independent immune recognition mechanisms is therefore crucial for enhancing treatment responses and improving clinical outcomes...

Jin Ng, Yue You, Tina Zhang et al. · Cancer Cell · 0 citations

#gene editing Open access Jul 2026

Prime editing enables drug-controllable T-cell therapies with clinical immunosuppression.

A multiplex prime-editing platform is developed that converts commonly used immunosuppressive drugs into tools for in vivo control of T-cell therapies via defined, pathway-specific drug resistance, enabling selective in vivo modulation in settings where immunosuppression cannot be withdrawn.

E. Bandala-Sanchez, Emma V. Petley, K. Ramsay et al. · Blood · 0 citations